USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Optibiotix Limited

USPTO PatentsView assignee record - 10 granted patents across 11 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

13.1

Avg claims per patent

+300%

5-year filing velocity

The verdict

Optibiotix holds 10 US patents across 11 technology areas, rank #27,051 of 50,000 tracked assignees.

#27,051
of 50,000 US assignees by volume: Top 61%
by Innovation Score (31.9/100): 13.1
avg claims per patent: +300%
filing velocity, last 5 yrs

Portfolio overview

Optibiotix Limited has been granted 10 US utility patents between 2018 and 2025, placing Optibiotix Limited at rank #27,051 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Optibiotix Limited is one of the more focused assignees in the PatentsView dataset. By volume, Optibiotix sits between One Home Brands, Inc. (10 patents, rank #27,047) and Oxford Instruments AFM Inc (10 patents, rank #27,055) - the closest US assignees by grant volume. The composite Innovation Score of 31.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 8 grants, compared with 2 in the 2015–2019 window, a +300% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Optibiotix Limited's 13.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Optibiotix Limited against peers pursuing similar technology classes.

One Home Brands

10
One Lambda

10
One Star Internat…

10
Opla Energy

10
Orlandi

10
Out of Sight Visi…

10
Oxford Biomedica…

10
Oxford Instrument…

10
Optibiotix ◀

10

What this shows Optibiotix holds 10 patents at rank #27,051, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Optibiotix

By rank, the assignees closest to #27,051 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Optibiotix's primary technology class.

Optibiotix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

32 Top 61% higher than 39% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Optibiotix Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	10.0%
2019	1	10.0%
2020	2	20.0%
2021	2	20.0%
2023	1	10.0%
2024	2	20.0%
2025	1	10.0%

Which technologies does Optibiotix Limited patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 9

A23L - FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF 9

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 9

A23V - INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION 9

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 4

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 3

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 3

C12R - INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS 2

A23C - DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF 2

C12Y - ENZYMES 1

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 1

Top 11 of 11 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Accelerating

Where it ranks

Overall rank by patents

#27,051

Across all tracked assignees

Innovation Score

31.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Optibiotix Limited hold?

Optibiotix Limited holds 10 US granted patents filed between 2018 and 2025, spanning 11 technology areas.

What is Optibiotix Limited's Innovation Score?

Optibiotix Limited has an Innovation Score of 31.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Optibiotix Limited focus on?

Optibiotix Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 9 patents. The company has filed patents in 11 CPC subclasses total.

Is Optibiotix Limited's patent filing rate increasing or decreasing?

Optibiotix Limited's recent filing velocity is +300% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for Optibiotix Limited's patents?

Optibiotix Limited's patents average 13.1 claims each. This falls within the standard range, providing solid legal coverage.

How is the Optibiotix Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Optibiotix's 10 grants land it in the top 61% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Optibiotix ranks #27,051 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.